These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202 [TBL] [Abstract][Full Text] [Related]
45. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. den Hollander JG; van Arkel C; Rijnders BJ; Lugtenburg PJ; de Marie S; Levin MD J Antimicrob Chemother; 2006 Jun; 57(6):1248-50. PubMed ID: 16556632 [TBL] [Abstract][Full Text] [Related]
46. Antifungal therapy of Aspergillus invasive otitis externa: efficacy of voriconazole and review. Parize P; Chandesris MO; Lanternier F; Poirée S; Viard JP; Bienvenu B; Mimoun M; Méchai F; Mamzer MF; Herman P; Bougnoux ME; Lecuit M; Lortholary O Antimicrob Agents Chemother; 2009 Mar; 53(3):1048-53. PubMed ID: 19104029 [TBL] [Abstract][Full Text] [Related]
47. Acremonium vertebral osteomyelitis: molecular diagnosis and response to voriconazole. Keynan Y; Sprecher H; Weber G Clin Infect Dis; 2007 Jul; 45(1):e5-6. PubMed ID: 17554690 [TBL] [Abstract][Full Text] [Related]
48. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Trifilio S; Singhal S; Williams S; Frankfurt O; Gordon L; Evens A; Winter J; Tallman M; Pi J; Mehta J Bone Marrow Transplant; 2007 Sep; 40(5):451-6. PubMed ID: 17589527 [TBL] [Abstract][Full Text] [Related]
49. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Cordonnier C; Maury S; Pautas C; Bastié JN; Chehata S; Castaigne S; Kuentz M; Bretagne S; Ribaud P Bone Marrow Transplant; 2004 May; 33(9):943-8. PubMed ID: 15034546 [TBL] [Abstract][Full Text] [Related]
50. Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis. Kobayashi K; Kami M; Murashige N; Kishi Y; Fujisaki G; Mitamura T Haematologica; 2004 Nov; 89(11):ECR42. PubMed ID: 15533847 [No Abstract] [Full Text] [Related]
51. [A case of orbital apex syndrome caused by localized invasive aspergillosis successfully treated with voriconazole]. Kuga A; Oishi K; Ishida H; Kanda F Rinsho Shinkeigaku; 2007 May; 47(5):207-10. PubMed ID: 17585601 [TBL] [Abstract][Full Text] [Related]
52. Peripheral neuropathy in patients on long-term triazole antifungal therapy. Baxter CG; Marshall A; Roberts M; Felton TW; Denning DW J Antimicrob Chemother; 2011 Sep; 66(9):2136-9. PubMed ID: 21685202 [TBL] [Abstract][Full Text] [Related]
53. Topical voriconazole solution for cutaneous aspergillosis in a pediatric patient after bone marrow transplant. Klein KC; Blackwood RA Pediatrics; 2006 Aug; 118(2):e506-8. PubMed ID: 16816005 [TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan. Saito T; Fujiuchi S; Tao Y; Sasaki Y; Ogawa K; Suzuki K; Tada A; Kuba M; Kato T; Kawabata M; Kurashima A; Sakatani M; Infection; 2012 Dec; 40(6):661-7. PubMed ID: 22956473 [TBL] [Abstract][Full Text] [Related]
55. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409 [TBL] [Abstract][Full Text] [Related]